[1]
|
A. W. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff, C. Hoffman, J. Rothrock, M. Lopez, H. Joshua, E. Harris, A. Patchett, R. Monaghan, S. Currie, E. Stapley, G. Albers-Schonberg, O. Hensens, J. Hirshfield, K. Hoogsteen, J. Liesch and J. Springer, “Mevinolin: A Highly Potent Competitive Inhibitor of Hydroxymethylglutaryl-Co-Enzyme a Reductase and a Cholesterol-Lowering Agent,” Proceeding of the National Academy of Sciences, Vol. 77, No. 7, 1980, pp. 3957-3961. doi:10.1073/pnas.77.7.3957
|
[2]
|
I. Chibata, K. Okumura, S. Takeyama and K. Kotera, “Lentinacin: A New Hypocholesterolemic Substance in Lentinus Edodes,” Experientia, Vol. 25, No. 12, 1969, pp. 1237-1238. doi:10.1007/BF01897467
|
[3]
|
T. Rokujo, H. Kikuchi, A. Tensho, Y. Tsukitani, T. Takenawa, K. Yoshida and T. Kamiya, “Lentysine: A New Hypolipidemic Agent from A Mushroom,” Life Sciences, Vol. 9, No. 7, 1970, pp. 379-385. doi:10.1016/0024-3205(70)90240-7
|
[4]
|
Y. Kabir, M. Yamaguchi and S. Kimura, “Effect of Shiitake (Lentinus Edodes) and Maitake (Grifola Frondosa) Mushrooms on Blood Pressure and Plasma Lipids of Spontaneously Hypertensive Rats,” Journal of Nutritional Science and Vitaminology, Vol. 33, No. 5, 1987, pp. 341-346.
|
[5]
|
T. Kaneda and S. Tokuda, “Effect of Various Mushroom Preparations on Cholesterol Levels in Rats,” Journal of Nutrition, Vol. 90, No. 4, 1966, pp. 371-376.
|
[6]
|
S. Suzuki and S. Ohshima, “Influence of Shiitake (Lentinus Edodes) on Human Serum Cholesterol,” Proceedings of the 9th International Scientific Congress on the Cultivation of Edible Fungi, Tokyo, 1974, pp. 463-467.
|
[7]
|
Y. Shimada, T. Morita and K. Sugiyama, “Eritadenine-Induced Alterations of Plasma Lipoprotein Lipid Concentrations and Phosphatidylcholine Molecular Species Profile in Rats Fed Cholesterol-Free and Cholesterol-Enriched Diets,” Bioscience, Biotechnology and Biochemistry, Vol. 67, No. 5, 2003, pp. 996-1006. doi:10.1271/bbb.67.996
|
[8]
|
K. Sugiyama, A. Yamakawa, H. Kawagishi and S. Saeki, “Dietary Eritadenine Modifies Plasma Phosphatidylcholine Molecular Species Profile in Rats Fed Different Types of Fat,” Journal of Nutrition, Vol. 127, No. 4, 1997, pp. 593-599.
|
[9]
|
K. Takashima, K. Izumi, H. Iwai and S. Takeyama, “The Hypocholesterolemic Action of Eritadenine in the Rat,” Atherosclerosis, Vol. 17, No. 3, 1973, pp. 491-502. doi:10.1016/0021-9150(73)90039-7
|
[10]
|
K. Takashima, C. Sato, Y. Sasaki, T. Morita and S. Takeyama, “Effect of Eritadenine on Cholesterol Metabolism in the Rat,” Biochemical Pharmacology, Vol. 23, No. 2, 1974, pp. 433-438. doi:10.1016/0006-2952(74)90434-1
|
[11]
|
S. R. Byrn, R. R. Pfeiffer, G. Stephenson, D. J. W. Grant and W. B. Gleason, “Solid-State Pharmaceutical Chemistry,” Chemistry of Materials, Vol. 6, No. 8, 1994, pp. 1148-1158. doi:10.1021/cm00044a013
|
[12]
|
J. Lu and S. Rohani, “Polymorphism and Crystallization of Active Pharmaceutical Ingredients (Apis),” Current Medicinal Chemistry, Vol. 16, No. 7, 2009, pp. 884-905. doi:10.2174/092986709787549299
|
[13]
|
A. Hakkinen, K. Pollanen, M. Karjalainen, J. Rantanen, M. Louhi-Kultanen and L. Nystrom, “Batch Cooling Crystallization and Pressure Filtration of Sulphathiazole: The Influence of Solvent Composition,” Biotechnology and Applied Biochemistry, Vol. 41, No. 1, 2005, pp. 17-28. doi:10.1042/BA20040044
|
[14]
|
M. Kitamura, “Polymorphism in the Crystallization of L-Glutamic Acid,” Journal of Crystal Growth, Vol. 96, No. 3, 1989, pp. 541-546. doi:10.1016/0022-0248(89)90049-3
|
[15]
|
S. Byrn, R. Pfeiffer and J. Stowell, “Solid State Chemistry of Drugs,” 2nd Edition, SSCI, Inc., West Lafayette, 1999.
|
[16]
|
J. Enman, U. Rova and K. A. Berglund, “Quantification of the Bioactive Compound Eritadenine in Selected Strains of Shiitake Mushroom (Lentinus Edodes),” Journal of Agricultural Food Chemistry, Vol. 55, No. 4, 2007, pp. 1177-1180. doi:10.1021/jf062559+
|
[17]
|
N. J. Leonard and K. L. Carraway, “5-Amino-5-Deoxyribose Derivatives. Synthesis and Use in the Preparation of ‘Reversed’ Nucleosides,” Journal of Heterocyclic Chemistry, Vol. 3, No. 4, 1966, pp. 485-489.
|
[18]
|
P. A. Levene and E. T. Stiller, “Acetone Derivatives of d-Ribose. Ⅱ.,” Journal of Biological Chemistry, Vol. 106, 1934, pp. 421-429.
|
[19]
|
M. Kawazu, T. Kanno, S. Yamamura, T. Mizoguchi and S. Saito, “Studies on the Oxidation of ‘Reversed Nucleosides’ in Oxygen. I. Synthesis of Eritadenine and Its Derivatives,” Journal of Organic Chemistry, Vol. 38, No. 16, 1973, pp. 2887-2890. doi:10.1021/jo00956a033
|
[20]
|
P. H. C. Eilers, “A Perfect Smoother,” Analytical Chemistry, Vol. 75, No. 14, 2003, pp. 3631-3636.
|
[21]
|
A. Cao, A. K. Pandya, G. K. Serhatkulu, R. E. Weber, H. Dai, J. S. Thakur, V. M. Naik, R. Naik, G. W. Auner, R. Rabah and D. C. Freeman, “A Robust Method for Automated Background Subtraction of Tissue Fluorescence,” Journal of Raman Spectroscopy, Vol. 38, No. 9, 2007, pp. 1199-1205.
|
[22]
|
R. Suryanarayanan and S. Rastogi, “Encyclopedia of Pharmaceutical Technology,”2006. http://informahealthcare.com/
|
[23]
|
A. P. Ayala, “Polymorphism in Drugs Investigated by Low Wavenumber Raman Scattering,” Vibrational Spectroscopy, Vol. 45, No. 2, 2007, pp. 112-116. doi:10.1016/j.vibspec.2007.06.004
|
[24]
|
S. D. Clas, “The Importance of Characterizing the Crystal Form of the Drug Substance During Drug Development,” Current Opinion in Drug Discovery and Development, Vol. 6, No. 4, 2003, pp. 550-560.
|
[25]
|
E. Fukuoka, M. Makita and Y. Nakamura, “Glassy State of Pharmaceuticals. 5. Relaxation During Cooling and Heating of Glass by Differential Scanning Calorimetry,” Chemical and Pharmaceutical Bulletin, Vol. 39, No. 8, 1991, pp. 2087-2090.
|
[26]
|
P. Tong and G. Zografi, “Solid-State Characteristics of Amorphous Sodium Indomethacin Relative to Its Free Acid,” Pharmaceutical Research, Vol. 16, No. 8, 1999, pp. 1186-1192.
|
[27]
|
L. Yu, “Amorphous Pharmaceutical Solids: Preparation, Characterization and Stabilization,” Advanced Drug Delivery Reviews, Vol. 48, No. 1, 2001, pp. 27-42. doi:10.1016/S0169-409X(01)00098-9
|
[28]
|
B. C. Hancock and M. Parks, “What Is the True Solubility Advantage for Amorphous Pharmaceuticals?,” Pharmaceutical Research, Vol. 17, No. 4, 2000, pp. 397-404. doi:10.1023/A:1007516718048
|
[29]
|
T. Vasconcelos, B. Sarmento and P. Costa, “Solid Dispersions as Strategy to Improve Oral Bioavailability of Poor Water Soluble Drugs,” Drug Discovery Today, Vol. 12, No. 23-24, 2007, pp. 1068-1075. doi:10.1016/j.drudis.2007.09.005
|
[30]
|
J. Enman, K. Ramser, U. Roval and K. A. Berglund, “Raman Analysis of Synthetic Eritadenine,” Journal of Raman Specroscopy, Vol. 39, No. 10, 2008, pp. 1464-1468.
|
[31]
|
Y. Huang, J. Komoto, Y. Takata, D. Powell, T. Gomi, H. Ogawa, M. Fujioka and F. Takusagawa, “Inhibition of S-Adenosylhomocysteine Hydrolase by Acyclic Sugar Adenosine Analogue D-Eritadenine-Crystal Structure of S-Adenosylhomocysteine Hydrolase Complexed with D-Eritadenine,” Journal of Biological Chemistry, Vol. 277, No. 9, 2002, pp. 7477-7482. doi:10.1074/jbc.M109187200
|
[32]
|
S. R. Vippagunta, H. G. Brittain and D. J. W. Grant, “Crystalline Solids,” Advanced Drug Delivery Reviews, Vol. 48, No. 1, 2001, pp. 3-26. doi:10.1016/S0169-409X(01)00097-7
|
[33]
|
A. Nangia and G. R. Desiraju, “Pseudopolymorphism: Occurrences Of Hydrogen Bonding Organic Solvents in Molecular Crystals,” Chemical Communications, No. 7, 1999, pp. 605-606. doi:10.1039/a809755k
|